Catch up on stories from the past week (and beyond) at the Slashdot story archive

 



Forgot your password?
typodupeerror
×

Comment Re:I trust (Score 1) 910

If, instead, parents were given freedom of choice in schools and teachers, the good ones would be oversubscribed, the poor ones undersubscribed and laid off / fired, and quality would improve dramatically and quickly.

So how are you going to choose who gets into the oversubscribed "good" schools? Ability to pay? What's actually going to happen is that the "good" schools all end up in nice little wealthy enclaves, which pushes up the property prices there just nicely. The "poor" schools end up even more starved of funding than they are now, so can only afford to hire the useless teachers who can't get a job anywhere else. Congratulations! You've just effectively ended any chance of social mobility!

Comment Re:Crowdsourcing (Score 1) 556

Kickstarter works very well for small projects. It seems to work OKish for medium-size projects - there was a recent Slashdot article about someone getting ~$1M for development of a sequel to a popular old computer game.

However, developing a new drug is going to cost you at least $100M, and probably closer to $1B[*]. How the hell do you think you're going to raise that much?

[*] Yes, I know there are articles out there by loons that claim the "actual cost" of drug development is $2.50 plus the handful of small change that we found down the back of the couch. They're talking crap. AstraZeneca spent US$24B over the last 12 years on R&D, and has released 3 new drugs in that time. if you want another data point, Cancer Research UK, an enormous UK-based charity, spent >£200M last year on research. It's spent roughly that much every year for the last 20 years (accounting for inflation). Do you know how many drugs they've developed? None.

Comment No, because there's no money in it (Score 2) 140

Developing a new drug takes hundreds of millions of dollars. Suppose you spend that and you some up with a completely new class of antibiotics. You've now got two problems. Firstly, for 99.9% of the infections out there the existing antibiotics work very well and are now generic, meaning low cost. Quite apart from that, no clinician is going to prescribe your new "last resort" antibiotic for someone coming in with a sniffle: you keep it in reserve for the people with vancomycin-resistant MRSA. The combination of these two means that your total market is maybe a couple of thousand people per year. You've just burnt>US$500M on development costs, so how are you going to get that money back? The solution to the antibiotic problem is to quit misusing the ones that we already have. Nobody's going to develop new ones any time soon.

Comment Re:Worrying state of affairs (Score 1) 374

You're missing something - VAT is only charged on the final sale, to the consumer. All businesses (above a certain size: ~$100K turnover) are VAT registered. This means that they pay no VAT on things that they buy, but have to collect VAT on things that they sell, unless they are selling to another VAT-registered company. It's basically the same as the state sales taxes that you have in the US - business-to-business transactions don't have to include state sales tax.

Comment Re:We need *new* antibiotics. (Score 1) 193

OK, let's crunch the numbers. A new class of antibiotics is going to cost you round at least $1Bn to develop[*]. Suppose you spend that and discover a totally new class, with no existing bacterial resistance. So, the clinical choices here are (a) prescribe it to every schmuck who thinks it might make his flu get better (and feed it to cows as well - why not?), or (b) give it only to people who are dying of MRSA. Option (a) is stupid as within ten years MRSA is now resistant to your new antibiotic as well, and the FDA (quite rightly) won't sanction it. Option (b) means that your total market is maybe 5,000 people per year in the western world. How are you going to recoup your $1Bn? This "pharma aren't interested in making you better" meme is a pile of crap. Pharma are interested in anything that will make them money. The first company to bring a cure-all for cancer to market is going to make so much cash that they'll drown in it. However, antibiotics are a place the the wonderful free market just fails. Unless there is some sort of subsidy, significant numbers of new antibiotics aren't going to be developed unless the drug resistance problem gets a whole lot worse.

[*] Yes, I know there are pointless Salon articles claiming that the real cost is 47 cents. They're talking bollocks.

Comment Re:Patents aren't helping (Score 1) 437

Their $55M estimate is a complete fantasy, though. If it were that cheap, there would be an awful lot more new drugs out there. There aren't. For example, go to http://www.nytimes.com/2011/03/07/business/07drug.html?_r=3&ref=general&src=me&pagewanted=all and look at the graphic. Over the last decade, there have been on average 20 new drugs approved per year. If each one only cost $55M, then any one of the twenty biggest pharma companies could have afforded the lot out of small change. Given the financial trouble that all of them are currently in with existing drugs coming off-patent, you have to wonder why they haven't been doing that.

Comment Re:Ambiguities (Score 2, Informative) 110

And how is this different to the USA refusing to recognise or honour European copyrights for most of its history? Charles Dickens' novels were widely published in the US without any payment whatsoever to him. It's only when the US developed a big enough internal copyright industry (who wanted their copyrights recognised in Europe) that any attention was paid to any non-Americal "intellectual property". Before that, the USA "took it all for free whilst sat on their ass", as you so delicately put it.

Slashdot Top Deals

Living on Earth may be expensive, but it includes an annual free trip around the Sun.

Working...